Tavanex is developed by Zahra Vahdat Shariatpanahi.

What development phase is Tavanex in?

Tavanex is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Tavanex

Zahra Vahdat Shariatpanahi · FDA-approved active Small molecule Quality 0/100

Tavanex, marketed by Zahra Vahdat Shariatpanahi, is a drug with a key composition patent expiring in 2028. The primary strength of Tavanex lies in its current market presence, leveraging its patented composition. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Tavanex
Also known as	Levofluxacine
Sponsor	Zahra Vahdat Shariatpanahi
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results